Ron Squarer
CIK 1454001 · CEO · last filed 2026-07-15
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$2.37M
Companies
6
Total Filings
55
Lifetime Open-Market Net
-$1.72M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| NUVL | Director | 0 | $123.96 | $0 | $0 | 3 | 2026-07-15 |
| ADCT | Director | 138,627 | $1.09 | $151.8K | -$20.2K | 5 | 2026-06-03 |
| TVTX | Director | 39,375 | $56.23 | $2.21M | $0 | 6 | 2026-05-21 |
| Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | Director | — | $25.59 | — | $0 | 12 | 2024-06-11 |
| Travere Therapeutics, Inc. (RTRX) Delisted | Director | 11,875 | — | — | $0 | 4 | 2020-05-19 |
| HOSPIRA INC (HSP) Delisted | Chief Commercial Officer | 19,563 | — | — | -$1.70M | 6 | 2011-02-28 |
Recent Filings · Page 2 of 6
55 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2024-06-14 | ADCT | Grant (A) | +40,000 | $0 | EDGAR |
| 2024-06-11 | Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | Disp (D) | — | $0 | EDGAR |
| 2024-05-10 | TVTX | Grant (A) | +6,500 | $0 | EDGAR |
| 2024-01-18 | Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-06-23 | Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | Grant (A) | — | $0 | EDGAR |
| 2023-05-19 | TVTX | Grant (A) | +4,500 | $0 | EDGAR |
| 2023-01-19 | Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-06-24 | Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | Grant (A) | — | $0 | EDGAR |
| 2022-05-12 | TVTX | Grant (A) | +3,000 | $0 | EDGAR |
| 2022-01-20 | Deciphera Pharmaceuticals, Inc. (DCPH) Delisted | Grant (A) | — | $0 | EDGAR |
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.